Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
100.00%
Operating Margin
81.89%
Net Margin
12.90%
Efficiency Metrics
Revenue per Expense Ratio
5.45
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
-36.03%
Income Tax Rate
0.00%
EPS
0.1200000000
Balance Sheet Analysis
Current Ratio
2.80
Cash Ratio
1.23
Working Capital
$83.28M
Debt to Equity
0.00
Debt to Assets
0.06%
Equity Ratio
57.21%
Cash Flow Analysis
Operating Cash Flow Ratio
90.16%
Free Cash Flow Ratio
90.16%
CapEx to Revenue
0.00%
Dividends Paid
$133.95M
Stock Buybacks
$193.95M
Total Shareholder Returns
$327.90M
Cash Position Change
-100.00%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Increased R&D investment by 100.00%
Detailed Growth Metrics
Core Performance
Revenue
125.52%
Net Income
103.24%
EPS
103.37%
Operating Income
121.22%
Operational Efficiency
R&D Expenses
100.00%
SG&A Expenses
223.85%
Operating Cash Flow
-24.74%
Free Cash Flow
-24.74%
Balance Sheet Health
Assets
-5.37%
Debt
-88.61%
Book Value per Share
-2.81%
Inventory
-100.00%
Shareholder Returns
Dividends per Share
-32.69%
Shares Outstanding
-0.01%
Long Term Trends
3Y Revenue/Share
41.05%
5Y Revenue/Share
601.84%
3Y Dividend/Share
-31.27%
5Y Dividend/Share
-34.34%